Etomidate
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Etomidate: From Anesthetic Induction to Headache Disorder
One-Sentence Summary
Etomidate is an injectable anesthetic agent used to induce general anesthesia, and it is currently marketed in Singapore. The TxGNN model predicts it may be effective for headache disorder, but this is a computational prediction only, with 0 clinical trials and 0 publications supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the Singapore license text. Anesthetic induction is inferred from the known use of the drug. |
| Predicted New Indication | Headache disorder |
| TxGNN Prediction Score | 98.39% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Etomidate is known as a GABA-A receptor positive allosteric modulator (beta2/beta3 subunit-selective) and is used for anesthetic induction. It is also known to inhibit 11β-hydroxylase, which suppresses adrenal steroid production.
GABAergic modulation is a speculative link to headache pathophysiology, but no mechanistic or clinical study was found to support it. The high TxGNN score (0.984) is a graph-based association only. Etomidate is given only by injection for anesthesia, so chronic or outpatient use for headache would be impractical.
Other top-ranked predictions are also computational only and lack a plausible rationale. They include mild and severe pre-eclampsia, trigeminal autonomic cephalalgia, alopecia, common cold, diffuse alopecia areata, congenital hypotrichosis milia, hypotrichosis simplex of the scalp, and exercise-induced malignant hyperthermia. For exercise-induced malignant hyperthermia, etomidate is generally regarded as a non-triggering anesthetic. That is a safety-compatibility point, not evidence of treatment.
Clinical Trial Evidence
Currently no related clinical trials registered for headache disorder.
Literature Evidence
Currently no related literature available for headache disorder.
Two articles were retrieved for lower-ranked predictions. Neither supports repurposing:
- PMID 39569044 (2024, JCEM Case Reports, case report): inhaled etomidate and its analogues from electronic cigarettes caused acquired 11β-hydroxylase deficiency that mimicked congenital adrenal hyperplasia. It documents an adverse endocrine effect, not a benefit for alopecia.
- PMID 39993848 (2025, Air Medical Journal, stability study): droplet formation in emergency drugs under extreme cold. It is a handling topic with no relevance to treating the common cold.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN08849P | ETOMIDATE-LIPURO INJECTION 20 mg/10 ml (B. Braun Melsungen AG) | Injection | Not stated in the available record |
Safety Considerations
- Disease associations flagged in the knowledge graph (not label text): adrenocortical insufficiency, Addison disease and hypotensive disorder are listed as contraindication-type associations.
- Known adrenal effect: Etomidate inhibits 11β-hydroxylase and can suppress adrenal steroid production. This is a particular concern in critically ill patients, including obstetric patients, which matters for the pre-eclampsia predictions.
- Drug Interactions: 39 potential interactions were identified, but their severity levels are unclassified. Those listed include morphine, dexamethasone, hydrocortisone, prednisolone, epinephrine, atropine, metoclopramide, ondansetron and several proton pump inhibitors (omeprazole, pantoprazole, lansoprazole).
Please refer to the package insert for the full warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a graph-based score. There are no clinical trials or supporting literature, and no mechanistic link to headache disorder has been shown. Etomidate's injection-only anesthetic use and its adrenal suppression liability make repurposing unattractive without new evidence.
To proceed, the following is needed:
- Singapore package insert warnings and contraindications (safety screening cannot proceed without them)
- Detailed mechanism of action data (MOA)
- Preclinical or mechanistic evidence linking GABA-A modulation to headache disorder
- A route and dosing feasibility assessment, since current use is injectable and anesthetic only
- A risk assessment for adrenal suppression in any proposed new population
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.